126 related articles for article (PubMed ID: 38233124)
21. Role of serum surfactant protein-D as a prognostic predictor in fibrotic hypersensitivity pneumonitis.
Ejima M; Okamoto T; Suzuki T; Miyazaki Y
Respir Investig; 2022 May; 60(3):369-378. PubMed ID: 34998715
[TBL] [Abstract][Full Text] [Related]
22. Prognostic role of blood KL-6 in rheumatoid arthritis-associated interstitial lung disease.
Kim HC; Choi KH; Jacob J; Song JW
PLoS One; 2020; 15(3):e0229997. PubMed ID: 32163457
[TBL] [Abstract][Full Text] [Related]
23. Krebs von den Lungen-6 as a biomarker for disease severity assessment in interstitial lung disease: a comprehensive review.
d'Alessandro M; Bergantini L; Cameli P; Vietri L; Lanzarone N; Alonzi V; Pieroni M; M Refini R; Sestini P; Bonella F; Bargagli E
Biomark Med; 2020 Jun; 14(8):665-674. PubMed ID: 32613855
[No Abstract] [Full Text] [Related]
24. Prospective Study of Drug-induced Interstitial Lung Disease in Advanced Breast Cancer Patients Receiving Everolimus Plus Exemestane.
Willemsen AECAB; Tol J; van Erp NP; Jonker MA; de Boer M; Meek B; de Jong PC; van Moorsel C; Gerritsen WR; Grutters JC; van Herpen CML
Target Oncol; 2019 Aug; 14(4):441-451. PubMed ID: 31325105
[TBL] [Abstract][Full Text] [Related]
25. KL6 and IL-18 levels are negatively correlated with respiratory function tests and ILD extent assessed on HRCT in patients with systemic sclerosis-related interstitial lung disease (SSc-ILD).
Sieiro Santos C; Antolín SC; Lorenzo JC; Garay CL; Morales CM; de Miguel EB; Guerrero MR; Herránz LS; Álvarez ED
Semin Arthritis Rheum; 2024 Apr; 65():152366. PubMed ID: 38290372
[TBL] [Abstract][Full Text] [Related]
26. Usefulness of serum Krebs von den Lungen-6 for the management of myositis-associated interstitial lung disease.
Takanashi S; Nishina N; Nakazawa M; Kaneko Y; Takeuchi T
Rheumatology (Oxford); 2019 Jun; 58(6):1034-1039. PubMed ID: 30624752
[TBL] [Abstract][Full Text] [Related]
27. Lung ultrasound B-lines and serum KL-6 correlate with the severity of idiopathic inflammatory myositis-associated interstitial lung disease.
Wang Y; Chen S; Lin J; Xie X; Hu S; Lin Q; Zheng K; Du G; Huang X; Zhang G; Gargani L; Matucci-Cerinic M; Furst DE
Rheumatology (Oxford); 2020 Aug; 59(8):2024-2029. PubMed ID: 31794028
[TBL] [Abstract][Full Text] [Related]
28. Nivolumab-induced interstitial lung disease analysis of two phase II studies patients with recurrent or advanced non-small-cell lung cancer.
Kato T; Masuda N; Nakanishi Y; Takahashi M; Hida T; Sakai H; Atagi S; Fujita S; Tanaka H; Takeda K; Satouchi M; Namba Y; Tamura T
Lung Cancer; 2017 Feb; 104():111-118. PubMed ID: 28212992
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of the Diagnostic Efficacies of Serological Markers KL-6, SP-A, SP-D, CCL2, and CXCL13 in Idiopathic Interstitial Pneumonia.
Xue M; Guo Z; Cai C; Sun B; Wang H
Respiration; 2019; 98(6):534-545. PubMed ID: 31665737
[TBL] [Abstract][Full Text] [Related]
30. Serum B cell-activating factor (BAFF) level in connective tissue disease associated interstitial lung disease.
Hamada T; Samukawa T; Kumamoto T; Hatanaka K; Tsukuya G; Yamamoto M; Machida K; Watanabe M; Mizuno K; Higashimoto I; Inoue Y; Inoue H
BMC Pulm Med; 2015 Sep; 15():110. PubMed ID: 26424433
[TBL] [Abstract][Full Text] [Related]
31. Clinical analysis and outcome of interstitial lung disease complicated with juvenile dermatomyositis and juvenile polymyositis.
Sato S; Uejima Y; Nanbu M; Suganuma E; Takano T; Tanaka R; Kabuki T; Oguma E; Oh-Ishi T; Kawano Y
Mod Rheumatol; 2017 Jul; 27(4):652-656. PubMed ID: 27588444
[TBL] [Abstract][Full Text] [Related]
32. Radiographic features and poor prognostic factors of interstitial lung disease with nivolumab for non-small cell lung cancer.
Saito Y; Sasaki S; Oikado K; Tominaga J; Sata M; Sakai F; Kato T; Iwasawa T; Kenmotsu H; Kusumoto M; Baba T; Endo M; Fujiwara Y; Sugiura H; Yanagawa N; Ito Y; Sakamoto T; Ohe Y; Kuwano K
Cancer Sci; 2021 Apr; 112(4):1495-1505. PubMed ID: 33098725
[TBL] [Abstract][Full Text] [Related]
33. Granuloma-forming interstitial pneumonia occurring one year after the start of everolimus therapy.
Saito Y; Kunugi S; Suzuki Y; Narita K; Miura Y; Minegishi Y; Kimura G; Kondo Y; Azuma A; Fukuda Y; Gemma A
Intern Med; 2013; 52(2):263-7. PubMed ID: 23318860
[TBL] [Abstract][Full Text] [Related]
34. Serum KL-6 level is a prognostic marker in patients with anti-MDA5 antibody-positive dermatomyositis associated with interstitial lung disease.
Ye Y; Fu Q; Wang R; Guo Q; Bao C
J Clin Lab Anal; 2019 Oct; 33(8):e22978. PubMed ID: 31301087
[TBL] [Abstract][Full Text] [Related]
35. Characteristics of patients with primary Sjögren's syndrome associated interstitial lung disease and relevant features of disease progression.
Zhang T; Yuan F; Xu L; Sun W; Liu L; Xue J
Clin Rheumatol; 2020 May; 39(5):1561-1568. PubMed ID: 31902032
[TBL] [Abstract][Full Text] [Related]
36. The role of lung ultrasound B-lines and serum KL-6 in the screening and follow-up of rheumatoid arthritis patients for an identification of interstitial lung disease: review of the literature, proposal for a preliminary algorithm, and clinical application to cases.
Wang Y; Chen S; Zheng S; Lin J; Hu S; Zhuang J; Lin Q; Xie X; Zheng K; Zhang W; Du G; Zhang G; Hoffmann-Vold AM; Matucci-Cerinic M; Furst DE
Arthritis Res Ther; 2021 Aug; 23(1):212. PubMed ID: 34391465
[TBL] [Abstract][Full Text] [Related]
37. Usefulness and performance evaluation of serum KL-6 and SP-A assays in healthy individuals and patients with interstitial lung disease.
Cho EJ; Hong J; Hyun J; Lee W; Kim HS; Chun S; Min WK
Clin Biochem; 2023 Aug; 118():110609. PubMed ID: 37414329
[TBL] [Abstract][Full Text] [Related]
38. Surfactant protein D and KL-6 as serum biomarkers of interstitial lung disease in patients with scleroderma.
Hant FN; Ludwicka-Bradley A; Wang HJ; Li N; Elashoff R; Tashkin DP; Silver RM;
J Rheumatol; 2009 Apr; 36(4):773-80. PubMed ID: 19286849
[TBL] [Abstract][Full Text] [Related]
39. Serum levels of Krebs von den Lungen-6 as a promising marker for predicting occurrence and deterioration of systemic sclerosis-associated interstitial lung disease from a Chinese cohort.
Cao XY; Hu SS; Xu D; Li MT; Wang Q; Hou Y; Zeng XF
Int J Rheum Dis; 2019 Jan; 22(1):108-115. PubMed ID: 30592376
[TBL] [Abstract][Full Text] [Related]
40. Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer.
Nakanishi Y; Masuda T; Yamaguchi K; Sakamoto S; Horimasu Y; Nakashima T; Miyamoto S; Tsutani Y; Iwamoto H; Fujitaka K; Miyata Y; Hamada H; Okada M; Hattori N
Respir Investig; 2019 Sep; 57(5):451-459. PubMed ID: 31248832
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
